US › Healthcare

Cartesian Therapeutics Inc. (RNAC)

US · Healthcare · Biotechnology

$8.06+2.41%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$78,000
Revenue YoY
-92.9%
Net profit
$-39.2M
Profit YoY
-121.2%
EPS
$-0.95
EPS estimate
$-0.70
Net margin
-50,233.3%

EPS came in at -0.95 against a street estimate of -0.70 — a miss of 35.7%.

Key statistics

Market cap
$231.2M
Forward P/E
25.1
P/B
31.26
Book value
$-5.19
EPS (TTM)
$-5.80
52-week high
$12.25
52-week low
$5.60
50-day MA
$8.30
200-day MA
$7.57
Beta
0.56

Analyst view

Analysts rate Cartesian Therapeutics Inc. a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $34.57.

Shareholding

Insiders
53.68%
Institutions
24.64%

Largest institutional holders

FundStake
Squarepoint Ops LLC7.62%
FMR Inc2.72%
BlackRock Inc2.04%
Vanguard Capital Management, LLC1.39%
683 Capital Management LLC1.12%
Millennium Management LLC0.97%
Geode Capital Management, LLC0.90%
Marshall Wace Asset Management Ltd0.85%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cartesian Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.